Neurocrine Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

12.09.23	Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont (RTTNews)
12.09.23	Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) (PR Newswire)
11.09.23	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults (PR Newswire)
08.09.23	NASDAQ Composite Index-Titel Neurocrine Biosciences-Aktie: So viel Gewinn hätte eine frühe Investition in Neurocrine Biosciences abgeworfen (finanzen.ch)
01.09.23	NASDAQ Composite Index-Wert Neurocrine Biosciences-Aktie: So viel Verlust hätte ein frühes Neurocrine Biosciences-Investment eingebracht (finanzen.ch)
31.08.23	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
29.08.23	Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and ... (PR Newswire)
28.08.23	Neurocrine Reveals New Data On Ingrezza With Improvements In HD Chorea In Huntington's Disease (RTTNews)
28.08.23	Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease (PR Newswire)
25.08.23	NASDAQ Composite Index-Papier Neurocrine Biosciences-Aktie: So viel Verlust hätte ein frühes Neurocrine Biosciences-Investment eingebracht (finanzen.ch)
18.08.23	Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease (PR Newswire)
18.08.23	NASDAQ Composite Index-Titel Neurocrine Biosciences-Aktie: So viel Verlust hätte ein frühes Investment in Neurocrine Biosciences bedeutet (finanzen.ch)
11.08.23	NASDAQ Composite Index-Papier Neurocrine Biosciences-Aktie: So viel Gewinn hätte ein frühes Investment in Neurocrine Biosciences eingefahren (finanzen.ch)
04.08.23	NASDAQ Composite Index-Titel Neurocrine Biosciences-Aktie: So viel Verlust hätte ein frühes Neurocrine Biosciences-Investment eingebracht (finanzen.ch)
01.08.23	Neurocrine Biosciences Inc Q2 Earnings Summary (RTTNews)
01.08.23	Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance (PR Newswire)
31.07.23	Ausblick: Neurocrine Biosciences informiert über die jüngsten Quartalsergebnisse (finanzen.net)
28.07.23	NASDAQ Composite Index-Papier Neurocrine Biosciences-Aktie: So viel Verlust hätte ein frühes Investment in Neurocrine Biosciences bedeutet (finanzen.ch)
21.07.23	NASDAQ Composite Index-Papier Neurocrine Biosciences-Aktie: So viel Gewinn hätte ein frühes Investment in Neurocrine Biosciences eingebracht (finanzen.ch)
17.07.23	Erste Schätzungen: Neurocrine Biosciences stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
14.07.23	NASDAQ Composite Index-Titel Neurocrine Biosciences-Aktie: So viel hätten Anleger an einem frühen Neurocrine Biosciences-Investment verdient (finanzen.ch)
11.07.23	Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors (PR Newswire)
11.07.23	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results (PR Newswire)
15.06.23	Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 (PR Newswire)
08.06.23	Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
02.06.23	Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate (PR Newswire)
19.05.23	Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology (PR Newswire)
15.05.23	Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective D... (PR Newswire)
12.05.23	Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 (PR Newswire)
03.05.23	Neurocrine Biosciences Inc Q1 Earnings Summary (RTTNews)
02.05.23	Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference (PR Newswire)
02.05.23	Ausblick: Neurocrine Biosciences veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
01.05.23	Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week (PR Newswire)
18.04.23	Erste Schätzungen: Neurocrine Biosciences veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
12.04.23	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results (PR Newswire)
21.03.23	Neurocrine Biosciences to Present at the Stifel 2023 CNS Days (PR Newswire)
19.03.23	Schutz vor Bärenmarkt: Zu diesen Aktien raten Morgan Stanley-Analysten (finanzen.ch) Im derzeit schwierigen Marktumfeld haben Morgan Stanley-Analysten einige Aktien ausfindig gemacht, die für Anleger Chancen bieten könnten.» mehr
09.03.23	Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on... (PR Newswire)
09.03.23	Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference (PR Newswire)
08.03.23	Neurocrine Biosciences to Participate at Investor Conferences in March (PR Newswire)
03.03.23	Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychi... (PR Newswire)
07.02.23	Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
06.02.23	Neurocrine Biosciences Inc Q4 Earnings Summary (RTTNews)
06.02.23	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 (PR Newswire)
22.01.23	Erste Schätzungen: Neurocrine Biosciences gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
17.01.23	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
09.01.23	Neurocrine, Voyager To Advance Multiple Gene Therapies For Neurological Diseases Treatment (RTTNews)
03.01.23	Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
22.12.22	Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease (PR Newswire)
06.12.22	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

mehr

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell
28.08.24		Schwacher Handel: NASDAQ Composite zum Handelsstart schwächer